louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04755855: Prospective Sinonasal Cancer Multi-institution Study
Official title: Sinonasal Cancer Study to Evaluate Oncologic Outcomes and Quality of Life
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Sinonasal Carcinoma
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2021-02-16
Enrollment: 200
Sex: ALL
Minimum age (years): 30
Maximum age (years): 99
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients undergoing treatment for sinonasal cancers

Brief summary: This is a multi-institution prospective study of patients with sinonasal malignancies. The goal of this study is to learn more about the course of sinonasal cancer, treatment outcomes, and patient quality of life. In addition, central mutational and genomic analysis of tumor tissue will be evaluated.


Eligibility criteria: Inclusion Criteria:

* Subjects between the ages of 30 days (non-inclusive) and 99 years (inclusive)
* Patients with a diagnosis of sinonasal cancer
* Patients undergoing treatment at Mayo Clinic

Exclusion Criteria:

* Healthy individuals
* Unwilling to sign the informed consent

Primary outcomes:
measure: Oncologic outcomes as measured by overall survival, disease specific survival and recurrence free survival
timeFrame: Through study completion, an average of 5 years
Secondary outcomes:
measure: Quality of life outcomes including the University of Washington Quality of Life Questionnaire (UW-QOL v4) and the Sinonasal Outcome Test 22 (SNOT22)
timeFrame: Through study completion, an average of 5 years
measure: Describe the molecular foundation of sinonasal malignancies utilizing RNA sequencing to identify transcriptomic tumor profiles
timeFrame: Through study completion, an average of 5 years
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic in Rochester
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Carlos Pinheiro Neto, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01738555: A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects
Official title: An Open-label, 36-week Extension Study on Amdoxovir at 500 mg Bid or 300 mg Bid in Combination With Zidovudine and Lopinavir/Ritonavir in HIV-1 Treatment-experienced Subjects With M184I/V Mutation in Addition to 0-2 Confirmed Thymidine Analog Mutations.
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Human Immunodeficiency Virus Infection
Keywords: amdoxovir
zidovudine
HIV
HAART
antiretroviral
Lead sponsor: RFS Pharma, LLC
Sponsor class: INDUSTRY
First posted: 2012-11-30
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is an open-label extension of RFSP-AMDX-2010 study for those subjects who received treatment with amdoxovir (300 mg or 500 mg twice daily) for 12 weeks and benefited from it. This study will examine the safety and efficacy of the investigational HIV drug, amdoxovir (300 mg and 500 mg bid doses; N = up to 30) in combination with zidovudine and lopinavir/ritonavir for 36 weeks.

Subjects will continue to receive either amdoxovir 300 mg twice daily or amdoxovir 500 mg twice daily, each in combination with zidovudine 300 mg twice daily and lopinavir/ritonavir (400 mg/100 mg twice daily) for additional 36 weeks.


Eligibility criteria: Inclusion Criteria:

* Must have completed Study RFSP-AMDX-2010 and received treatment with amdoxovir (500 mg bid or 300 mg bid) for 12 weeks before entry into study RFSP-AMDX-2012.
* Must have maintained ≥ 1.0 log10 copies/mL from baseline at Week 12 in Study RFSP-AMDX-2010.
* Must not have had any serious adverse experience since enrollment in Study RFSP-AMDX-2010, whether or not considered to be study drug-related.

Exclusion Criteria:

* Subjects who require ongoing therapy of nephrotoxic drugs or competitors of renal excretion.
* Subjects who require therapy with hematologic, bone marrow suppressive or cytotoxic agents.
* Subjects who require medications that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with life-threatening adverse events.
* Known allergy/sensitivity or any hypersensitivity to components of study drugs or their formulations.
* Women who are pregnant or breastfeeding.

Primary outcomes:
measure: HIV-1 viral load
timeFrame: up to 48 Weeks
Secondary outcomes:
measure: Incidence of adverse events
timeFrame: up to 48 Weeks
measure: Changes in Immunologic Function (CD4 cell counts)
timeFrame: from baseline to Weeks 18, 24, 30, 36, 42, 48
Other outcomes:
Locations:
Study officials:
affiliation: RFS Pharma, LLC
name: Luz Pascual, MD MPH
role: STUDY_DIRECTOR
References:
Clinical trial NCT00002655: Cryosurgery in Treating Patients With Liver Cancer or Liver Metastases
Official title: Cryosurgical Destruction of Surgically Incurable Liver Tumors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Liver Cancer
Metastatic Cancer
Keywords: localized unresectable adult primary liver cancer
recurrent adult primary liver cancer
liver metastases
Lead sponsor: University of Colorado, Denver
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2004-08-11
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: RATIONALE: Cryosurgery kills cancer cells by freezing them during surgery.

PURPOSE: Phase I/II trial to study the effectiveness of cryosurgery in treating patients with unresectable primary liver cancer or liver metastases.

Detailed description: OBJECTIVES: I. Assess the safety and efficacy of liquid nitrogen necrosis of liver lesions using a commercially available intraoperative cryosurgical system, with placement of the cryoprobe and subsequent monitoring by high-resolution ultrasound. II. Use this technique on selected patients with surgically unresectable metastatic or primary liver cancer whose disease appears confined to the liver and who are potentially curable if all tumor in the liver can be destroyed. III. Quantitate the quality and duration of survival, identify recurrence of hepatic malignant disease, and identify any morbidity from the procedure.

OUTLINE: Cryosurgery. Liquid nitrogen freezing of tumor using a cryoprobe placed and maintained under ultrasound guidance.

PROJECTED ACCRUAL: 50 patients will be treated.

Eligibility criteria: DISEASE CHARACTERISTICS: Biopsy-proven metastatic or primary malignant disease of the liver No extrahepatic regional or distant metastases No primary tumors commonly associated with local spread or metastases to other sites, e.g.: Gastric cancer Pancreatic cancer Breast cancer Lung cancer Liver lesions considered unresectable because of location in relation to major vascular structures or involvement of multiple hepatic segments Tumor extent and location such that cryosurgery expected to destroy all tumor and render patient disease-free Tumor volume no greater than 50% of total hepatic volume on CT No more than 12 lesions

PATIENT CHARACTERISTICS: Age: Over 21 Other: Overall health permitting safe laparotomy Blood/body fluid analyses and imaging/exams for tumor measurement within 1 month prior to registration

PRIOR CONCURRENT THERAPY: Prior liver resection, radiotherapy, or chemotherapy allowed

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Denver
country: United States
facility: University of Colorado Cancer Center
state: Colorado
Study officials:
affiliation: University of Colorado, Denver
name: Greg V. Stiegmann, MD
role: STUDY_CHAIR
References:
Clinical trial NCT03795155: Prospective Genomics Initiative on Multiple Synchronous Lung Cancer (PGI-MSLC)
Official title: Prospective Genomics Initiative on Multiple Synchronous Lung Cancer (PGI-MSLC)
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Multiple Synchronous Lung Cancers (MSLCs)
Lead sponsor: RenJi Hospital
Sponsor class: OTHER
First posted: 2019-01-07
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Clinical diagnosis of multiple synchronous lung cancers (MSLCs)

Brief summary: This prospective study is to characterize the genomic landscape and genetic heterogeneity of multiple synchronous lung cancer (MSLC) in correlation with comprehensive clinical, histopathological and medical imaging information, in order to improve disease diagnosis and tailored treatment for MSLC patients.

Detailed description: * To initiate a prospective registry of MSLC patients with high-quality clinical samples and detailed medical data.
* To define the clonal relationship, genomic landscape and potential driver alterations of MSLC using whole-genome sequencing.
* To determine the intrapatient and intratumor genetic heterogeneity of MSLC.
* To correlate molecular features with clinical parameters and patient outcome.
* To serve as a continuous infrastructure for a large variety of research purposes including: A. Diagnostic research B. Prognostic research C. Biological research D. Interventional trial design testing new therapies in MSLC.

Eligibility criteria: Inclusion Criteria:

* Age 18 years or older
* Confirmed diagnosis of multiple synchronous lung cancers (MSLCs) without metastatic disease
* Signed informed consent

Exclusion Criteria:

* Medical or psychiatric condition that would preclude informed consent
* History of known high-risk infections
* With metastatic tumors except lung

Primary outcomes:
measure: Genomic characters of synchronous lessions in each MSLC patient
timeFrame: November 30, 2021
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University
state: Shanghai
Study officials:
affiliation: Ren Ji Hospital
name: Xiaojing Zhao, M.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Ren Ji Hospital
name: Yujie Fu, Ph.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Ren Ji Hospital
name: Guanglei Zhuang, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Ma P, Fu Y, Cai MC, Yan Y, Jing Y, Zhang S, Chen M, Wu J, Shen Y, Zhu L, Chen HZ, Gao WQ, Wang M, Gu Z, Bivona TG, Zhao X, Zhuang G. Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancer. Nat Commun. 2017 Oct 10;8(1):823. doi: 10.1038/s41467-017-00963-0.
Clinical trial NCT01312155: Assisted Intubation
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Intubation Conditions
Keywords: endotracheal
intubation
video
time
Lead sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
Sponsor class: OTHER
First posted: 2011-03-10
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients undergoing general anesthesia with endotracheal intubation

Brief summary: The study investigates assisted intubation using a videolaryngoscope in anesthesia.


Eligibility criteria: Inclusion Criteria:

* Easy airway assessment

Exclusion Criteria:

* Difficult airway
* ASA 3

Primary outcomes:
measure: Performance
timeFrame: 3 months
Secondary outcomes:
measure: Time
timeFrame: 3 months
Other outcomes:
Locations:
city: Montreal
country: Canada
facility: MUHC
state: Quebec
Study officials:
affiliation: MUHC - McGill
name: Thomas Hemmerling, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05479955: Skin-to-skin Contact Time and Maternal Psychology
Official title: The Effect of Skin to Skin Contact Time After Childbirth on Fear of Child Birth, Birth Trauma and Maternal Attachment: A Single-blind Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Skin to Skin Contact
Lead sponsor: Mersin University
Sponsor class: OTHER
First posted: 2022-07-29
Enrollment: 110
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The aim of this study was to determine the effect of postpartum skin-to-skin contact time on fear of childbirth, birth trauma and maternal attachment.

Detailed description: This is a single-blind, randomized controlled trial. Data were collected from 110 women who gave birth in the gynecology clinic of a public hospital in southern Turkey between September 2021 and February 2022. Participants who met the inclusion criteria were informed about the purpose of the study and skin-to-skin contact, informed consent was obtained from those who agreed to participate, and the women were divided into groups according to a 1:1 computer-based randomization program. Data were collected at the time of consent to the study, within the first hour after birth, 24 hours after birth, 4 weeks postpartum, and 4 months postpartum. Collected by the first author. The CONSORT directive was followed in the planning, implementation and writing of the research.

Eligibility criteria: Inclusion Criteria

* Must be able to a normal term vaginal delivery,
* Native language is Turkish,
* Have single fetus
* Must be able to skin to skin contact wit her baby

Exclusion Criteria

* Cesarean section,
* Complications,
* Psychological or psychiatric disorder,

Primary outcomes:
measure: Level of Fear of Childbirth
timeFrame: Postpartum with in 4th- 24th hours
measure: Level of Birth Trauma
timeFrame: Postpartum 4th weeks
measure: Level of Maternal Attachment
timeFrame: Postpartum 4th weeks
measure: Level of Birth Trauma
timeFrame: Postpartum 4th month
measure: Level of Maternal Attachment
timeFrame: Postpartum 4th month
Secondary outcomes:
Other outcomes:
Locations:
city: Mersin
country: Turkey
facility: Gozde Gokce Isbir
Study officials:
affiliation: Mersin University
name: Gozde Gokce Isbir
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06158555: Targeted Perfusion Based Haemodynamic Management in Critically Ill Patients Using Urethral Perfusion
Official title: Targeted Perfusion Based Haemodynamic Management in Critically Ill Patients Using Urethral Perfusion - a Pilot Study
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Critically Ill
Lead sponsor: King's College Hospital NHS Trust
Sponsor class: OTHER
First posted: 2023-12-06
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: To assess the safety and feasibility of the IKORUS device in critically ill patients and to gather exploratory data on haemodynamic coherence


Eligibility criteria: Inclusion Criteria:

* Within 24 h of ICU admission
* Predicted length of ICU stay at least 5 days
* Receiving \>0.1 mcg/kg/min of noradrenaline at time of study enrolment

Exclusion Criteria:

* Palliative treatment intent
* Contra indication to urethral catheterisation or complication during previous urethral catheter insertion
* Contraindication to fluid or vasopressor challenges in the opinion of the attending clinician

Primary outcomes:
measure: Change to Urethral Perfusion Index
timeFrame: 5 minutes after fluid challenge administration
Secondary outcomes:
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: King's College Hospital
Study officials:
References:
Clinical trial NCT02778555: Development and Validation of a Daily Pain Catastrophizing Scale
Official title: Development and Validation of a Daily Pain Catastrophizing Scale Based Measure
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Chronic Pain
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2016-05-20
Enrollment: 713
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adults with chronic pain.

Brief summary: This study sought to develop and validate a brief, daily version of the Pain Catastrophizing Scale.

Detailed description: The Pain Catastrophizing Scale (PCS; 13 items; factors: rumination, helplessness, magnification) (Sullivan 1995) measures trait catastrophizing in the context of actual or anticipated pain. Currently, there is no validated tool for measuring pain catastrophizing at the daily level. Lack of a validated daily measure stands as a barrier for studies that aim to characterize mechanisms of pain treatment and how PC adaptation / change occurs.

Eligibility criteria: Inclusion Criteria:

1. Age 18 or above
2. Chronic pain of any etiology
3. Online access
4. Ability to participate in daily measurements over 14 days

Exclusion Criteria:

1. Lack of ability to answer questionnaires and daily catastrophizing captures, at the discretion of study staff.

Primary outcomes:
measure: Factor Analysis & PROMIS Correlation for Samples 2 & 3
timeFrame: 14 days
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Stanford University
name: Beth D Darnall, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Darnall BD, Sturgeon JA, Cook KF, Taub CJ, Roy A, Burns JW, Sullivan M, Mackey SC. Development and Validation of a Daily Pain Catastrophizing Scale. J Pain. 2017 Sep;18(9):1139-1149. doi: 10.1016/j.jpain.2017.05.003. Epub 2017 May 19.
Clinical trial NCT01174355: A Study of ND0801 in Attention Deficit/Hyperactivity Disorder (ADHD)
Official title: A Multicenter, Open Label, Escalating Dose Study to Assess the Tolerability and the Safety and to Explore the Efficacy and the Pharmacokinetics of ND0801 in Adult Patients With Attention Deficit/Hyperactivity Disorder (ADHD)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Attention Deficit and Hyperactivity Disorder
Lead sponsor: NeuroDerm Ltd.
Sponsor class: INDUSTRY
First posted: 2010-08-03
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A multicenter, open label, escalating dose study to assess the tolerability and the safety and to explore the efficacy and the pharmacokinetics of ND0801 in adult patients with attention deficit/hyperactivity disorder (ADHD).


Eligibility criteria: Inclusion Criteria:

* Outpatients.
* Men and women 18-55 years of age.
* Primary DSM-IV diagnosis of adult ADHD confirmed by senior physician
* Capable and willing to provide informed consent
* Able to adhere to the treatment schedule, and withdrawal of ongoing pharmacotherapy for the treatment of ADHD prior to the beginning of the study treatment and during the study drug treatment.
* Subjects must be able to read, hear, write and speak the local language.
* Subject has signed a written informed consent to participate in the study.

Exclusion Criteria:

* Unstable or significant medical disorder.
* Current (within 12 months of baseline) primary or secondary depression.
* History of substance abuse or dependence within the past 6 months
* Any psychotic disorder (lifetime), including schizoaffective disorder, or major depression with psychotic features
* Bipolar disorder
* Eating disorder
* Obsessive compulsive disorder
* Post-traumatic stress disorder
* Current generalized anxiety disorder
* Presence of a personality disorder
* Individuals with a significant other neurological disorder.
* Use of any investigational drug within 4 weeks of the randomization visit
* Known or suspected pregnancy
* Women who are breast-feeding
* Women of childbearing potential and not using a medically accepted form of contraception

Primary outcomes:
measure: Safety & Tolerability Evaluation
timeFrame: 1 week
Secondary outcomes:
Other outcomes:
Locations:
city: Haifa
country: Israel
facility: Rambam Hospital
city: Hod Hasharon
country: Israel
facility: Shalvata Mental Health Center (SMHC)
Study officials:
References:
Clinical trial NCT01297855: Colistin Plus Rifampicin in MDR P. Aeruginosa and A. Baumanii
Official title: Randomized Controlled Trial of Colistin Versus Colistin Plus Rifampicin in MDR P.Aeruginosa and A.Baumanii
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Drug Safety
Lead sponsor: Mahidol University
Sponsor class: OTHER
First posted: 2011-02-17
Enrollment: 130
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In Siriraj Hospital, Colistin alone for treatment of MDR. A.baumanii or P.aeruginosa contributed to mortality 45%. In vitro studies revealed synergism of Rifampicin and Colistin.

In this study, patients with documented MDR. P.aeruginosa or A.baumanii will be allocated to receive Colistin alone and another group will receive Colistin plus Rifampicin.


Eligibility criteria: Inclusion Criteria:

* Age\>18 years
* Hospitalized to Siriraj Hospital
* Infection with MDR A.baumanii or P.aeruginosa
* Nescessary for treatment with Colistin
* Patient agrees to participate by giving written informed consent.

Exclusion Criteria:

* pregnancy or lactating mother
* Colistin or Rifampicin allergy
* Active hepatic disease or abnormal liver function test
* patient who suspected infection with mycobacterium tuberculosis
* patient who can not drug by enteral feeding

Primary outcomes:
measure: number of subjects with cure or improvement
timeFrame: up to day 28
Secondary outcomes:
measure: number of subjects with eradication of causative bacteria
timeFrame: up to day 28
Other outcomes:
Locations:
city: Bangkoknoi
country: Thailand
facility: Division of Infectious disease and Tropical Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital
state: Bangkok
Study officials:
affiliation: Siriraj Hospital
name: Sukij Piyasirisilp, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03372655: Prognostic Factors Affecting Duchenne Muscular Dystrophy
Official title: Prognstic Factors Affecting Duchenne Muscular Dystrophy
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Duchenne Muscular Dystrophy
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2017-12-14
Enrollment: 82
Sex: MALE
Minimum age (years): 10
Maximum age (years): 18
Standard ages: CHILD
ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Male patient diagnosed as duchenne muscular dystrophy by typical clinical picture\&shooting serum CPK level \& EMG study or biopsy

Brief summary: Determination of prognostic factors affecting ambulation of duchenne muscular dystrophy

Detailed description: Duchenne muscular dystrophy is the most common herditary muscular disease , it lead to loss of ambulation in early teenageers . It lead to early death at the mean age of 19 years

Eligibility criteria: Inclusion Criteria:

* any male pt diagnosed as duchenne muscular dystrophy by typical clinical picture \&shooting serum CPK level \&EMG study or biopsy \& age 10 to 18yrs old

Exclusion Criteria:

* female patient ' age below 10 yrs old or above 18 yrs old .patient with autoimmune disease or malignancy

Primary outcomes:
measure: Ten meter walking test
timeFrame: 2018 - 2019
Secondary outcomes:
measure: Muscle strenght
timeFrame: 2018- 2019
Other outcomes:
Locations:
Study officials:
References: